Related Experiment Video
Updated: Aug 22, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors
Xiaomei Wang1, Norman G Nagl, Stephen Flowers
1Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Abstract:
Human SWI/SNF complexes use the energy of ATP hydrolysis to remodel chromosomes and alter gene expression patterns. The activity of the complexes generally promotes tissue-specific gene expression and restricts cell proliferation. The ATPase that drives the complexes, BRG1, is essential for tumor suppression in mice and deficient in a variety of established human tumor cell lines. The complex contains at least 7 other core components, one of which is a large subunit designated p270. p270 RNA is expressed in all normal human tissues examined, but protein expression is severely reduced in at least 2 human tumor lines, C33A and T47D. We show here that loss of p270 in the C33A and T47D cell lines is evident at the RNA level as well as the protein level. The implication that p270 can be informatively screened at the RNA level made a high-efficiency cancer profiling array approach to screening human tumors feasible. Expression was screened in an array containing RNA-derived cDNA from 241 tumor and corresponding matched normal tissues from individual patients. p270 deficiency was observed at a higher overall frequency than BRG1 deficiency, but all tissues were not equally affected. Deficiency of p270 was observed most frequently in carcinomas of the breast and kidney. The results were most striking in kidney, where p270 expression was deficient in 30% of carcinoma samples screened. Screening of a panel of established human renal carcinoma-derived cell lines supports the frequency observed in the primary tumor tissue samples.
Insights
Deficiency in the SWI/SNF complex subunit p270 is linked to various human cancers, particularly breast and kidney carcinomas. This finding highlights p270 as a potential biomarker for cancer profiling.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Human SWI/SNF complexes, driven by BRG1, regulate gene expression and cell proliferation.
- BRG1 is crucial for tumor suppression, and its deficiency is noted in human tumor cell lines.
- p270 is a core component of the SWI/SNF complex, with reduced protein expression in some tumor lines.
Purpose of the Study:
- To investigate the expression levels of p270 in human tumor cell lines and primary tumors.
- To determine the frequency and tissue specificity of p270 deficiency in various cancers.
- To assess the potential of p270 as a biomarker for cancer profiling.
Main Methods:
- Analysis of p270 RNA and protein expression in human tumor cell lines (C33A, T47D).
- Development and application of a high-efficiency cancer profiling array using RNA-derived cDNA.
- Screening of 241 tumor and matched normal tissue samples from individual patients.
Main Results:
- Loss of p270 was observed at both RNA and protein levels in C33A and T47D cell lines.
- p270 deficiency occurred more frequently overall than BRG1 deficiency across screened tissues.
- p270 deficiency was most prevalent in breast and kidney carcinomas, with 30% of kidney carcinomas showing deficiency.
Conclusions:
- p270 expression can be effectively screened at the RNA level, enabling large-scale cancer profiling.
- p270 deficiency is a significant finding in human cancers, particularly renal and breast carcinomas.
- p270 represents a promising biomarker for cancer screening and diagnosis.
